Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors. (25th February 2019)

• Record Type: Journal Article
• Authors: Klotz, Laura V.; Courty, Yves; Lindner, Michael; Petit‐Courty, Agnès; Stowasser, Anja; Koch, Ina; Eichhorn, Martin E.; Lilis, Ioannis; Morresi‐Hauf, Alicia; Arendt, Kristina A. M.; Pepe, Mario; Giopanou, Ioanna; Ntaliarda, Giannoula; Behrend, Sabine J.; Oplopoiou, Maria; Gissot, Valérie; Guyetant, Serge; Marchand‐Adam, Sylvain; Behr, Jürgen; Kaiser, Jan‐Christian; Hatz, Rudolf A.; Lamort, Anne‐Sophie; Stathopoulos, Georgios T.
• Is Part Of: Cancer medicine. Volume 8:Number 4(2019:Apr.)
• Page Start: 1486
• Page End: 1499
• Publication Date: 2019-02-25
• Subjects: LADC -- lung adenocarcinoma -- obstruction -- smoking -- survival; 616.994005
• DOI: 10.1002/cam4.2031
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early‐stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never‐smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians ( P < 0.0001). Ever‐smoker tumors were preferentially localized to the upper lobes. We observed 120 relapses and 74 deaths over 704 cumulative follow‐up years. Median overall and disease‐free survival were >7.5 and 3.6 years, respectively. Patients aged <45 or >65 years, resected >60 days postdiagnosis, with abnormal FVC/DLCO VA, N2/N3 stage, or solid histology had significantly decreased survival estimates. These were fit into a weighted locoregional LADC death risk score that outperformed pTNM7 in predicting survival in the GLAD and in our second cohort. We define the clinical gestalt of locoregional LADC and provide a new clinical tool to predict survival, findings that may aid future management and research design. Abstract : We designed a study that longitudinally profiled the phenotype of 366 patients with resected lung adenocarcinoma and identified multiple novel aspects of the phenotype of contemporary locoregional lung adenocarcinoma, such as its sex indifference, its striking upper lobe predominance, and the early timing of pleural relapse and we developed a simple clinical tool to predict survival that outperforms the current staging system.